यूनाइटेड किंगडम - अंग्रेज़ी - MHRA (Medicines & Healthcare Products Regulatory Agency)

sanofi consumer healthcare - dexamethasone sodium metasulfobenzoate; framycetin sulfate; gramicidin - ear/eye drops solution - 500microgram/1ml ; 5mg/1ml ; 50microgram/1ml

मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

royce pharma manufacturing sdn. bhd. - nicotinamide; calcium pantothenate; biotin; cyanocobalamin; thiamine hydrochloride/vit b1; pyridoxine hcl/vitamin b6; riboflavine -

माल्टा - अंग्रेज़ी - Medicines Authority

sanofi s.r.l viale l. bodio, 37/b 20158, milan, italy - framycetin sulfate, dexamethasone, gramicidin - eye drops, solution ear drops, solution - framycetin sulfate 0.5 % (w/v) dexamethasone 0.05 % (w/v) gramicidin 0.005 % (w/v) - ophthalmological and otological preparations

इसराइल - अंग्रेज़ी - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 300 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.

इसराइल - अंग्रेज़ी - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 150 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.

इसराइल - अंग्रेज़ी - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 200 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.

इसराइल - अंग्रेज़ी - Ministry of Health

inovamed ltd - quetiapine as fumarate - tablets prolonged release - quetiapine as fumarate 400 mg - quetiapine - quetiapine inovamed sr is indicated for the treatment of schizophrenia. quetiapine inovamed sr is effective in preventing relapse in stable schizophrenic patients who have been maintained on quetiapine inovamed sr. quetiapine inovamed sr is indicated for the treatment of moderate to severe manic episodes associated with bipolar disorder. quetiapine inovamed sr is indicated for the treatment of major depressive episodes in bipolar disorder. treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for preventing recurrence in bipolar disorder in patients whose manic, mixed or depressive episode has responded to quetiapine treatment, as monotherapy or in combination with lithium or sodium valproate. quetiapine inovamed sr is indicated for add-on treatment of major depressive episods in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy. prior to initiating treatment, clinicians should consider the safety profile of quetiapine inovamed sr.